has a place in the effort to avert acute attacks; however, its use is restricted within the allergic asthma subtype. The treatment of an already established exacerbation is more straight forward ...

Benralizumab is more effective than prednisolone in treating eosinophilic exacerbations in patients with asthma and COPD.

Treatment at the point of an exacerbation for this type of asthma has barely changed for over 50 years, with steroid drugs being the mainstay of medication. Steroids such as prednisolone can ...

Benralizumab can be used for the treatment of acute eosinophilic exacerbations of asthma and chronic obstructive pulmonary disease (COPD), according to a study published online Nov. 27 in The ...

We should like to emphasize the fact that this therapy is recommended only when the diagnosis of acute intractable bronchial asthma is certain since it might be hazardous if used in the treatment ...

For patients with COPD, budesonide-glycopyrrolate-formoterol does not improve clinical outcomes compared with fluticasone-umeclidinium-vilanterol.

The Department of Health (DOH) has so far recorded 46 cases of bronchial asthma and acute exacerbation nationwide and this ...

Corticosteroid + long-acting beta-2 agonist (LABA). Allow approx. 12hrs between doses. Asthma: ≥12yrs: initially 1 inh of 100/50 or 250/50 or 500/50 twice daily, based on disease severity and ...

Asthma and COPD exacerbations cause nearly four million deaths worldwide each year, but treatment for the chronic conditions has not changed in five decades, she noted. Reuters ...